POLA1 and diffuse large B-cell lymphoma: Beyond the frontline setting, polatuzumab has also shown efficacy in various combinations for relapsed/refractory DLBCL, including with bendamustine–rituximab [85], venetoclax [100], bispecific antibodies, and salvage chemotherapy regimens such as Pola-R-GemOx [87] and Pola-R-ICE [91,92].